Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Bionor releases updated investor presentation

Financial .2016

(Oslo, Norway, 21 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the company has updated its investor presentation.

Bionor provides update on funding

Financial .2016

(Oslo, Norway, 20 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the Board contemplates to launch a private placement of up to about NOK 70 million to be conducted within the end of this month. Further details on exact timing and structure of this transaction will be disclosed when the result of a pre-sounding phase has been concluded.

Bionor provides an update on scientific collaborations

Financial .2016

(Oslo, Norway, 13 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), today provides an update on scientific collaborations in relation to the company’s HIV immunotherapy pipeline. On 31 May 2016, the Board of Directors announced a clinical strategy with continued focus on HIV immunotherapy and functional cure, which are complex scientific areas, and best pursued through collaborative efforts.

Bionor releases updated investor presentation

Financial .2016

(Oslo, Norway, 21 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the company has updated its investor presentation.

Bionor provides update on funding

Financial .2016

(Oslo, Norway, 20 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the Board contemplates to launch a private placement of up to about NOK 70 million to be conducted within the end of this month. Further details on exact timing and structure of this transaction will be disclosed when the result of a pre-sounding phase has been concluded.

Bionor provides an update on scientific collaborations

Financial .2016

(Oslo, Norway, 13 June 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR), today provides an update on scientific collaborations in relation to the company’s HIV immunotherapy pipeline. On 31 May 2016, the Board of Directors announced a clinical strategy with continued focus on HIV immunotherapy and functional cure, which are complex scientific areas, and best pursued through collaborative efforts.

Go to news section

Featured content